Susan Little, MD is the Director of the UCSD Primary Infection Research Program, Director of the UCSD AIDS Clinical Trials Group Clinical Research Site, and Co-Director of the UCSD Antiviral Research Center. Dr. Little’s research interests include the pathogenesis, prevention, and treatment of acute and very recent HIV infection and the use of molecular epidemiologic methods to infer and characterize HIV transmission networks. She also studies factors that contribute to HIV transmission and novel diagnostic strategies to identify acutely infected individuals. She is actively involved in the training and mentoring of students, post-doctoral research fellows, and junior faculty. She is an investigator of the UCSD Center for AIDS Research (CFAR) and chairs the CFAR Ending the HIV Epidemic Scientific Working Group. She has recently taken an active role in the COVID-19 Prevention Network (CoVPN), leading Phase IIIefficacy trials for COVID-19 vaccines and monoclonal antibodies.
At the completion of this educational session, learners will:
- Understand the safety and efficacy of the Moderna and Pfizer derived from US Phase 3 clinical trials.
- Know how to counsel patients on the risks and benefits of receiving these mRNA vaccines.
- Be able to report adverse experiences in your patient population during post-licensure surveillance.
- Understand how current limitations in available data shape ongoing recommendations for nonpharmacologic interventions.
This CME activity has approved for AMA PRA Category 1 Credit™
for February 17, 2021 as a live activity. This activity will also be available as an enduring activity from February 18, 2021, through February 16, 2024.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Susan Little (Presenter) has no relevant financial relationships to disclose.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Click here to take the CME Evaluation and Post-Meeting Evaluation